The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets
Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis
Activation of the cannabinoid receptor type 2 reduce damages to the brain and disruptions to the spinal cord during ischemia-reperfusion injury
The endocannabinoid receptor CB2 is a regulator of trauma-inducing anxiety and a potential target for PTSD drugs.
Citral, a natural activator of the cannabinoid receptor type 2, can help combat pain and inflammatory conditions